Equities

JMS Co Ltd

7702:TYO

JMS Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)443.00
  • Today's Change0.00 / 0.00%
  • Shares traded8.20k
  • 1 Year change-13.98%
  • Beta0.6831
Data delayed at least 15 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

JMS CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and drugs. The Company operates through five geographical segments including Japan, Singapore, China, Philippines and Germany. The Company is engaged in the manufacture and sale of infusion and nutrition products, dialysis products, surgery products, blood and cell products and other products. The Company’s main products include infusion & transfusion set, syringe pump, surgical gown, dialysis kit, peritoneal dialysate, microcatheter, blood bag, among others. The Company is also involved in the provision of maintenance service and other related services.

  • Revenue in JPY (TTM)67.87bn
  • Net income in JPY-36.00m
  • Incorporated1947
  • Employees5.28k
  • Location
    JMS Co Ltd12-17, Kako-cho, Naka-kuHIROSHIMA-SHI 730-8652JapanJPN
  • Phone+81 822435844
  • Fax+81 822435997
  • Websitehttps://www.jms.cc/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Yamashita Health Care Holdings Inc62.72bn501.00m5.72bn606.0011.330.65737.950.0913197.83197.8324,816.183,411.072.6417.765.65103,493,400.002.112.235.746.4513.7412.460.79720.84721.01--0.0033.155.770.0071164.8432.063.8410.76
Leoclan Co Ltd19.80bn136.06m5.75bn176.0042.421.0322.630.290322.9622.963,346.78943.511.56368.493.41--1.222.192.384.8213.2210.820.78041.172.40-------25.64-11.32-49.85-28.60-19.34--
Precision System Science Co., Ltd.3.98bn-1.12bn7.72bn158.00--1.86--1.94-40.59-40.59144.04149.930.49261.585.4625,189,580.00-13.88-3.81-18.40-5.0923.8830.40-28.18-5.531.49-16.260.2488---24.60-1.9015.31---24.26--
Koken Ltd10.22bn565.86m7.93bn287.0013.570.61067.830.7764114.49114.492,066.952,545.070.49912.003.0135,597,010.002.763.703.414.7545.6946.695.547.191.8122.340.306825.88-0.16054.92-15.8414.33-39.876.96
Create Medic Co Ltd12.93bn888.98m8.77bn962.009.070.52065.700.678100.05100.051,446.831,742.180.68071.724.6413,440,170.004.683.005.453.5343.7645.366.884.603.47--0.050663.222.103.11-68.06-25.530.66271.12
DVx Inc47.25bn55.70m9.92bn316.00172.641.0921.180.20995.335.334,522.33842.242.0623.294.13149,530,700.000.24323.110.58267.5710.2211.600.11791.491.42--0.0047.57-3.442.57-81.53-29.2311.2315.81
EcoNaviSta Inc1.20bn281.96m10.53bn35.0041.383.2634.858.7838.6538.65170.53490.670.38961.5218.3634,260,280.009.16--9.85--66.17--23.51--15.45--0.00--21.55--38.02------
JMS Co Ltd67.87bn-36.00m10.96bn5.28k--0.26842.880.1614-1.47-1.472,772.011,650.800.82132.643.8012,847,620.00-0.05081.33-0.07381.9721.9524.29-0.06191.571.070.54190.383243.312.432.38-112.81---2.421.22
OLBA Healthcare Holdings Inc120.11bn1.50bn12.63bn1.35k7.991.086.070.1052252.91252.9120,250.401,863.862.8316.304.8088,710,020.003.533.0011.8910.3711.5011.291.251.040.9459742.060.21432.627.331.996.0914.11-2.5814.87
Seed Co Ltd33.28bn1.69bn14.10bn962.007.510.80332.880.423862.0462.041,188.74580.100.70452.807.7834,592,670.003.651.996.063.5143.1342.315.182.740.794911.280.596239.565.891.90721.4415.3020.424.56
HOSHI IRYO-SANKI CO., LTD15.10bn1.41bn14.43bn486.009.350.740611.690.9558451.24451.244,843.615,697.900.666727.375.9731,069,800.006.285.667.797.1948.8049.049.428.653.08--0.0016.347.256.4212.0110.04-13.238.45
Kusurinomadoguchi Inc9.91bn897.35m15.11bn505.0016.302.187.281.5284.4384.43943.55630.970.5277--3.0319,623,970.004.71--15.84--57.76--8.92----31.520.034--17.53--122.49------
Techno Medica Co Ltd10.34bn1.19bn15.91bn237.0010.860.925212.221.54167.16167.161,442.431,962.830.60312.254.4543,647,340.006.966.688.047.8049.9848.8611.5312.314.51138.020.0039.339.781.9617.154.190.71687.67
Daiken Medical Co Ltd9.84bn1.06bn16.05bn175.0013.661.9912.501.6336.8936.89342.51253.630.86933.903.8756,226,790.009.367.4413.2510.8441.3341.7410.779.281.90301.850.252771.356.713.0138.843.03-4.010.9806
Data as of Nov 22 2024. Currency figures normalised to JMS Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

7.90%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 07 Nov 2024561.70k2.27%
Dimensional Fund Advisors LPas of 07 Nov 2024552.25k2.23%
Nikko Asset Management Co., Ltd.as of 08 Nov 2024306.60k1.24%
Daiwa Asset Management Co. Ltd.as of 31 Oct 2024255.30k1.03%
Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024116.60k0.47%
BlackRock Japan Co. Ltd.as of 07 Nov 202453.60k0.22%
Dimensional Fund Advisors Ltd.as of 07 Nov 202443.97k0.18%
Asset Management One Co., Ltd.as of 07 Nov 202426.80k0.11%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 07 Nov 202426.40k0.11%
Nissay Asset Management Corp.as of 21 Feb 20239.70k0.04%
More ▼
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.